Kames Fish Farming, another Scottish trout farm operator, and Tethys Aquaculture, an aquaculture research impact company, will work on the RTFS project, with support from the Scottish Aquaculture Innovation Centre(SAIC). The vaccine was developed by the University of Stirling team as part of a five-year European Commission-funded project called ‘Targetfish’, in which Tethys Aquaculture acted as the project’s industry forum leader.
Dr Rowena Hoare from the University of Stirling’s Institute of Aquaculture said: “RTFS has been a major problem for the rainbow trout industry for decades. We are delighted that this project has been funded by SAIC, enabling our novel RTFS vaccine to be tested on two fish farm sites. We hope in the future to combine this with other vaccines to assist in the sustainability of the trout industry.”
RTFS is a common disease in trout and has been responsible for the substantial loss of stocks, with some sites reporting high average early-stage mortality rates. Rainbow trout is the second most-produced finfish by volume on UK fish farms, making RTFS a particularly important issue on British shores.
SEALICE ORAL VACCINE
We are delighted to be part of a two year project on the “Development of an orally administered novel sea lice vaccine targeting mucosal immunity” funded by the Scottish Aquaculture Innovation Centre (SAIC). The project is led by Dr. Sean Monaghan from the University of Stirling with the participation of the University of Maine, BioMar Limited, Sisaf Ltd, Tethys Aquaculture Limited and Moredun Research Institute.